Nautilus Biotechnolgy, Inc. (NAUT) Q2 2026 Earnings Report, Transcript and Summary

Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Second Quarter 2026 Earnings Call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like to turn the conference over to your speaker today, Ji-Yon Yi with the Gilmartin Group. Please go ahead.

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist and Anna Mowry, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on July 28, 2026. With that, I'll turn the call over to Sujal.

Thanks, Ji-Yon, and thank you all for joining us today. We spent the last 9 years building what I believe is one of the most innovative platforms in life sciences. It produces a layer of biological insight that we believe does not exist anywhere else in the world today. This is the conclusion we're hearing from a growing number of scientists once they see our data, and it's the reason I'm confident about where this company is headed. We believe that a platform this capable has many possible applications. We've walked you through them on these calls over the past few years. This quarter, I want to focus on a deliberate strategic realignment of where we point the platform and on the reasoning behind it. Let me start with the decision itself. We're moving a significant share of our R&D resources from our broad-scale application to our proteoform application. We're doing it for 2 reasons that reinforce each other. The first is genuine momentum. The scientific community is telling us directly in conference halls and in our own sales conversations that proteoform resolution is a critical, differentiated layer of biological insight and one we believe we can uniquely put in customers' hands today. The second is that broad scale needs more time, and I'll come back to that in a moment. Let me say more about that first. Since launch, we have seen strong and growing customer enthusiasm for the proteoform approach and the unique insight it can deliver, including numerous additional customer-requested proteoform targets. The feedback coming through our sales team this year has been consistent, and it represents what we believe to be a substantial commercial opportunity. Given the potential scale of that opportunity and our technical performance to date, we're significantly shifting resources across the company and putting a new roadmap in place to accelerate our proteoform applications. We're also going to lean harder into partnerships with pharma and academic institutions to push these capabilities further and faster than we could on our own. This is not a sudden shift. Anyone who's followed the company over the past year will recognize the trajectory that's been pushing us in this direction. When we set out to build our iterative mapping applications, we expected broad scale first and proteoform second. Our platform matured in the opposite order, and we've been turning the proteoform dial up quarter after quarter. Let me lay that trajectory out. A year ago, a preprint with our collaborators showed for the first time that we could measure tau proteoforms at a resolution no one had ever achieved. Next, we signed a collaboration with the Allen Institute for Brain Science to analyze human brain samples, spanning multiple brain regions, genetic backgrounds and disease severities. Our alpha instrument at the Buck Institute for Aging also began producing real biological data, and that data was presented at major scientific conferences, revealing biology in Alzheimer's that the field has chased for decades and never been able to see. In the first quarter, the Michael J. Fox Foundation funded us to build the next proteoform assay for Parkinson's and Baylor College of Medicine became our first early access customer for tau. And now, in the 2nd quarter, we recognize our first revenue from both Baylor College and the Michael J. Fox Foundation grant-funded development work. We also selected AKT1 as our 1st oncology proteoform assay, 1 of 3 oncology targets that have now cleared our development criteria. Parag will take you inside the science and the data behind each of these steps in a few minutes. Now, let me come back to the second reason, broad scale. Our broad proteome application is behind the timeline we set. In the 2nd quarter, we completed testing and determined that our assay configuration changes did not sufficiently improve probe candidate performance to support a 2027 general availability of our broadscale application at our target specifications. We have an exceptional team working on an extraordinarily hard problem, and hard science is unpredictable. Some of the development efforts we are undertaking next, which Parag will describe in detail, are inherently long in duration, on the order of several quarters. In the meantime, we're moving the majority of our application-specific R&D resources into proteoform development, keeping a focused team on the most critical parts of broadscale to keep advancing the program and reduce its key technical risks. Shifting resources from broadscale to proteoforms will impact the pace of development in broadscale, but given the opportunity we're seeing in proteoforms, that's a tradeoff that we're willing to make. Let me briefly touch on where this path could lead. As we continue to rapidly develop our proteoform portfolio and expand the capabilities of the assays, we believe new opportunities will arise that were not necessarily available to us with a broadscale first format. Two of them are worth planting a flag on, even though they're both very early. The first is the clinical market. Our original thinking with a broadscale first path was that the Nautilus Voyager would primarily be a research-use-only tool. Our customers would make discoveries on that platform and then build their own high-throughput, low-cost test that they could carry into the clinic. What we're hearing now with proteoform capabilities in customers' hands is different. Customers are excited, and they believe for key markers and key disease areas, proteoform measurements are likely to translate directly into clinical research and eventually into diagnostics. While it's not our current focus because there's no other platform that can make these measurements, it's conceivable that we could get pulled into the clinical market earlier than we planned, and we've begun to think about how to prepare for that. Second is pharma. As we expand our conversations with pharma, they are thinking hard about how to combine different data modalities with AI models and use the results to advance therapeutic development, building therapies faster with a higher likelihood of success. We expect that as pharma begins to further appreciate that our proteoform capabilities provide one of the deepest layers of biological insight into disease state and cellular function, we believe opportunities will emerge to partner with pharma to go after new targets, generate data sets to feed AI models and to add bespoke capabilities to existing assays that meet their specific needs. I want to be clear, both of these are early. And while we're not putting a plan or a timeline around either of them today, we are beginning to build toward them. Before turning it over to Parag, I want to reiterate that we have a platform that can deliver unique value to the market, and our customers are telling us that the most urgent need now is in proteoforms. Because of this, we've made a data-driven decision to concentrate on the value we can deliver today as quickly as we can. Parag will take you deeper into the science, and Anna will take you through the numbers before I close. Over to you, Parag.

Thanks, Sujal. I want to start with what we're hearing from customers, because it is directly shaping how we work. The heart of it is one word, resolution. Our proteoform assays measure the specific molecular states of a protein, its isoform composition and its patterns of modification at single-molecule resolution with the sensitivity and reproducibility that we believe that existing affinity assays and mass spectrometry methods cannot match. What customers tell us again and again is that this lets them see biology that was simply invisible to them before. Critically, proteoforms are more than just additional protein detail. The specific form a protein takes often determines everything that matters about it, where it goes in the cell, what complex it joins, what pathway it activates, what phenotype it ultimately drives. This is one of the reasons the field collectively has struggled to make progress in diseases like cancer and Alzheimer's. Without the ability to resolve biology at this level, the most important signals have stayed out of reach. Let me add additional color to the trajectory Sujal described. A year ago, our preprint with Genentech, Mount Sinai, and the Neural Stem Cell Institute showed for the first time that we could resolve the tau proteoform landscape at single-molecule resolution. Our alpha instrument at the Buck Institute then generated data at a median CV of roughly 5.5% against an industry norm closer to 25%. And that data showed that different APOE genetic risk variants carry distinct tau proteoform signatures. This is a striking result that we believe is only measurable on our platform. APOE is one of the best-known genetic risk factors in Alzheimer's, yet it had never been linked to tau at a mechanistic level. And we feel that the difference we resolved is invisible to pre-existing proteomics tools. We have also found that model systems widely used in Alzheimer's research show markedly different tau proteoform landscapes from one another, a distinction that we expect could prove critical to how drug developers choose their models. These are exactly the kinds of biological differences that bulk methods cannot see and that iterative mapping was built to reveal. They are the kinds of findings that have led researchers to describe our data in their own words as, quote, a game changer and as something that, quote, will become critical to their work. Now let me talk about oncology and specifically why we are leading with AKT1. In Q2, we narrowed our oncology work to 3 candidates, AKT1, EGFR, and p53 and developed them in parallel. All 3 cleared our reproducibility and accuracy criteria and moved into development, which is in itself an important proof point. It tells us our assay building methodology is now repeatable, not a one-time success with tau. AKT1 is furthest along, and we expect that it will be first to market. It is a compelling place to start for both scientific and commercial reasons. AKT1 sits at a control hub for cell growth and survival signaling. There is already a multi-billion-dollar market in the AKT-targeted therapies, but those therapies have shown mixed clinical results, largely because patient selection relies on indirect biomarkers rather than direct evidence that the pathway is actually driving a given tumor. Proteoform-level resolution provides that direct readout. We anticipate it will be able to identify the patients who are truly dependent on the pathway. In other words, this is a way to improve response rates for drugs that are already on the market with exactly the kind of insight existing proteomics cannot reach. That brings me to why we expect that we can expand the proteoform portfolio so quickly. Proteoform development is now bottlenecked by capacity, not by scientific uncertainty. We have what we believe is a proven template. We anticipate that the remaining unknowns on each new target are contained, so adding people should translate directly into more assay content and more capabilities delivered faster. The math is compelling. Our tau assay took about 5 years to build. Our first oncology markers reached that same technical bar in about a year. As we scale the team, we expect to add new assays at a cadence measured in months rather than years, growing from a small handful of assays today toward roughly 20 proteoform assays anticipated by the middle of 2028. That speed lets us be disciplined about where we go next. We are prioritizing neuroscience, oncology, immunology and cardiology. Within those areas, we look for targets with ready access to antibodies and a large market opportunity, which we assess through clinical trial activity, publications, NIH funding and direct customer input. Encouragingly, the demand we're hearing from customers lines up almost exactly with the internal target list we had already built. The scaled-up proteoform development team will aim to qualify new antibodies, build controls and immunoprecipitation protocols, develop and qualify new sample types and drive down the sample input required. Once we hit our performance criteria on a target, we plan to verify and validate the assay, bring in outside collaborators and move to early access. The reallocation of our assay development resources does two things. It gives us the potential to bring new assay content to market on a regular, predictable cadence instead of in occasional bursts, and it is expected to pull forward the enabling capabilities customers ask for most. In particular, lower sample input requirements and access to new sample types, including biofluids like cerebrospinal fluid and plasma. Biofluid access matters enormously because it is what unlocks the large majority of the biomarker market. Here is where that leaves the roadmap. Our tau proteoform assay stays in early access with general availability of consumable kits expected in mid-2027. Our AKT1 proteoforms assay is anticipated to enter early access in late 2026 with general availability expected in mid-2027. A second oncology proteoforms assay is in development, also targeting general availability in mid-2027. We expect a third oncology proteoform assay and continued expansion of the pipeline with additional kits reaching general availability expected in late 2027. On enabling capabilities, we expect to bring a roughly 100-fold reduction in required sample input into early 2027 and to enable cerebrospinal fluid for our tau assay in 2028. You should expect a rolling series of announcements, as new content and capabilities come online roughly every 6 months, increasingly driven by customer demand. Anna will connect that roadmap plan, including the instrument timeline and the revenue outlook. Turning to broadscale, the fundamentals of the program are solid. Our second quarter work reinforced the core premise that iterative mapping with trimer-based probes can decode the broad proteome, but that same testing made clear that our current assay configuration does not yet deliver the performance we need on the timeline we had targeted. Therefore, we have concluded it will not support a 2027 general availability at our target specifications. The remaining work concentrates in 3 areas. The first is our probe library. We have more than enough performant probes to move forward, but we need to increase their diversity through affinity maturation and inherently long lead time activity. The second is the machine learning layer, which keeps improving, as we feed it more on-platform data. The third is the assay architecture behind our configuration change, where we are working with our partners to stabilize the new assay platform so that we can detect true positive binding events more reliably. We are advancing these work streams in parallel. I am not going to put a new timeline on broadscale today, but the underlying science is sound, and the program keeps moving forward even as the bulk of our development effort now goes to proteoforms. One critical area to discuss is how we fit into the world of AI for bio. The field is racing to apply AI to biology, but that work is only as good as the data underneath it. The genome is a blueprint, but proteins are the machines that carry out the work, and their functional state is what determines how a drug binds, whether it is toxic, and which patients respond. That is precisely the layer today's models are missing because the data has never existed at the resolution and scale a model needs. We believe that the data that is needed is the data our platform produces. I'll leave it there for now, but it is a meaningful part of why the proteoform work excites me so much, well beyond any single assay. The world is desperate for differentiated data at scale. Before I hand it to Anna, let me place this in the broadest context I can. Every major advance in medicine has been unlocked by a new ability to read or write biology. Sequencing the genome gave us the foundation to identify genetic diseases faster than ever before. Our growing command of gene editing through tools like CRISPR has begun to deliver real relief from once intractable diseases. I believe the proteoform resolution that iterative mapping uniquely provides is the next of those key breakthroughs. And then over time, it will translate into meaningful advances in how we understand and treat human disease. With that, I'll turn the call over to Anna.

Thanks, Parag. Let me start with the commercial and customer picture, and then I'll take you through the numbers, the resource shift, and our expectations for the coming quarters. Our early access program continued to broaden this quarter, although the number of active paying projects is still small. We've also built a commercial organization, which now stands at 3 people, including our VP of Global Sales, and the number and quality of institutions in serious conversation with us has grown significantly. The sales team is in the field every day and they describe a level of enthusiasm and receptivity that they say they have not seen anywhere else in their careers. A word of caution on the near term. This is a new team running new sales cycles, and converting early interest into signed paying engagements will take time. Turning to revenue, which we are reporting for the first time this quarter. Total revenue was $0.2 million. The majority of that came from grant revenue from our Michael J. Fox Foundation-funded alpha-synuclein proteoform assay, with the remainder in service revenue from our first early access program project. As a reminder, the grant revenue funds development work, whose costs run through our R&D expense. And our early access engagements are designed primarily to give key opinion leaders access to our platform through a services model, not to generate meaningful revenue or margin at this stage. In practice, these are proof of concept studies. Customers are kicking the tires today with the goal that these early evaluations grow into larger ongoing engagements over time. For the full year, we are maintaining a revenue guidance of approximately $0.5 million. Total operating expenses were $15.9 million for the second quarter of 2026, a decrease of approximately 7% from the prior year period. Research and development expenses were $9.6 million, down approximately 8% from the prior year period, driven primarily by lower laboratory spending, lower stock-based compensation, and lower facilities costs. Selling, general and administrative expenses were $6.3 million, down approximately 6% from the prior year period, driven primarily by lower salaries and related benefits, reflecting reduced incentive compensation expectations for the year and lower stock-based compensation. Net loss for the second quarter of 2026 was $14.5 million or $0.11 earnings per share compared to a net loss of $15 million or $0.12 earnings per share in the prior year period. We continue to manage both operating expenses and cash prudently this quarter, and our results came in better than planned. In fact, we now expect full year operating expenses to come in below prior guidance, representing year-over-year growth of less than 10%. We ended the second quarter with $129.2 million in cash, cash equivalents and investments, compared to $143.4 million at the end of the first quarter, reflecting cash usage of approximately $14.2 million in the quarter. Based on our current trajectory, we believe our financial plan supports a cash runway that extends into the first quarter of 2028. Let me put some numbers behind the resource shift Sujal and Parag described. In headcount terms, we are effectively tripling the number of people focused on our proteoform development efforts, while reducing the broad scale team by roughly half. That shift shows up in our application-specific R&D effort, which was previously weighted heavily towards broadscale and is now roughly 2/3 proteoforms and 1/3 broadscale. The remainder of the R&D team works on elements of the platform common to every iterative mapping application, foundational work that benefits proteoforms and broadscale alike and that portion of the team is unchanged. Importantly, we are accelerating proteoform content and capability development and de-risking our path to commercialization, all within our planned spend envelope. Let me also connect the roadmap Parag described to the financials. In the near term, revenue is expected to continue to come primarily from grant funding and early access program services. On the platform, we remain on track to place a beta unit this year. From there, we expect to open the Voyager platform for pre-orders in early 2027, with shipments beginning in mid-2027, time to align with the proteoform assay consumable releases Parag outlined. That is when platform revenue begins. The inflection point in instrument sales and consumables pull-through comes as our portfolio broadens through 2027 and into 2028. We'll refine that outlook, as our portfolio and customer pipelines mature. Finally, on capital, our cash on hand is expected to support operations into the first quarter of 2028. That said, we anticipate some level of fundraising between now and mid-2027 to support our proteoform expansion and broader market development. We are evaluating a combination of debt and equity, and we intend to approach it in the most prudent way possible. I want to be clear though, we are not in a rush. We will raise when the combination of business catalysts and market conditions produces the best outcome for our company and our shareholders. Back to you, Sujal.

Thanks, Anna. Let me recap our priorities and why we believe this is the right strategic choice. We're putting the bulk of our resources behind proteoforms because that's where we can deliver unique value today. The message from our customers and the market is strong, and our plan is expected to expand our proteoform capability across more disease areas, more sample types, and more labs. We think this is also the fastest path to full commercialization. We believe that the science on proteoforms is largely behind us. What's left is execution and that enables a more predictable timeline to general availability. None of this diminishes broadscale. Measuring the entire proteome remains one of the large opportunities in our industry, and we intend to get there. We feel that the premise is sound, the remaining work is understood and a focused team is staying on the hardest technical risks. What has changed is sequencing, not conviction. Proteoforms now, because the market is asking for them and we believe we can deliver them. Broadscale when the technology is ready to deliver what customers need. We go into the second half with a clear mandate and cash expected to last into 2028. Our focus from here is delivering a wave of new proteoform assays with expanded capabilities, working alongside key opinion leaders and early customers to generate data and biological insight that cannot be generated elsewhere and scaling our business in parallel. We will keep you up to date as we go. Thank you for joining us today. And with that, we're happy to take your questions.

Excellent. Maybe just the first one, you've got 3 salespeople, $130 million in cash, and as you mentioned, like 7 quarters of cash, but you're looking to find the right time to raise. So just walk through how you guys titrate the ability to expand the teams necessary to drive the revenue traction you need in order to support the business. I'm just trying to understand. Anna mentioned some unlock events, I think, between now and mid-'27. Maybe can you just talk to a little bit about that pathway and kind of how you manage the burn versus the commercial opportunity.

Sure, maybe I'll tackle that, Dan. This is Sujal, and good morning to you. So I think -- first and foremost, I think what -- the way Anna and I think about this is making sure that the size of our commercial organization and those that are focused on talking to customers on a daily basis, making sure that team is right-sized for the serviceable opportunity that we have and being able to reach customers. One of the things, for example, that you see in our strategy is that the proteoforms that we are releasing today, even though they could be across oncology and neurodegenerative and cardiovascular and inflammatory disorders, it's concentrated in just two areas today. And that's to give us some efficiency in terms of who we're reaching out to, how we're going to market, what trade shows we're getting to. And so there's inherently efficiency built into this strategy to start with. And second, because the technology, this proteoform capability is so unique, what we're finding is that customers are very, very willing to have conversations to learn more about it. And so we're pretty comfortable right now with the team that we have. And just so you have a full sense of what that team looks like, I mean, there's Amber Faust who's our VP of Global Sales. There's a roughly East-West type of sales rep leader on each side of the country. And then as well, we have a couple of folks in scientific engagement and scientific affairs with -- who are out interfacing with customers on a daily basis as well. We feel very comfortable that, that core nucleus is good for the neurodegeneration work we're doing with tau and with the early work that we're doing on oncology. It's not my expectation that we'll add to that this year. But certainly next year, I think we'll get to the point where the business will have grown to the point where it'll demand adding some sales capability.

Could you elaborate a bit on the uniqueness of the approach in cancer and in neurology versus existing approaches? So you're saying you're going to see this pull from these customers because it's so unique and different. So maybe just elaborate a bit on just the key performance metrics about the platforms that are out there today doing this? And then the economics to the instrument cost, the assay cost. I know as you look to launch in '27, I think the instrument was a $1 million instrument. Just wondering like how that -- kind of how the profile on the economics for customers will look.

So, maybe Parag will take the first half of that question and then I'll dive in on the second half.

Yes, absolutely. I think one of the critical aspects to think about, Dan, is that there is no other platform in the world that can measure proteoforms at scale. The ability to discern a combination of an isoform plus multiple post-translational modifications is an attribute that is unique to our platform and our platform alone. But -- and so we've heard from customers things like, literally, I have always wanted to be able to measure that. I believe this is critical to understanding how signaling works, what therapeutics are likely to work, what patients are like -- need to be targeted by looking at that combination of isoforms and post-translational modifications together. And so that is an incredibly differentiated data type because we are literally the only platform in the world that can make the measurement at scale. And so when you start applying that to critical therapeutic targets, AKT1 being the one we're starting with, and then moving, as we mentioned, to other high priority targets, that this is something that from the customer side, they recognize immediately that this is an important measurement and something that they believe is critical to the core biological processes. And as a contrast, the existing players out there, either targeted or more broadscale, are focused dominantly on singular measurements. So antibody, aptamer measurements of total protein going up and down, and they lack this additional layer of detail that confers so much specificity to the measurement.

Thanks, Parag. Dan, to answer the second half of your question, the feedback that we have heard from customers through a few different market research studies that we've conducted and a formal content analysis on pricing show that the platform's capabilities even with just the proteoform content, as long as there are sufficient panels to have an instrument busy, it supports the case for an instrument at roughly the $1 million price point, which is the price point that we have stated as our target and it continues to be our target. As we open the instrument for -- instrument and platform for pre-orders at the beginning of next year, before that we will announce our final pricing. So it might move up or down a little, but roughly a $1 million for an instrument deal is what we expect for the instrument. And then, as we've previously said, depending on the assay and the target and so forth, the pricing might vary a little bit for the price per sample, but roughly a few thousand dollars a sample for kits for the platform.

Got it. And maybe I can sneak in one of these. So how do we think about therefore you're focusing on the AKT1. It's a $1 million instrument. Like, I mean, could you get 10 customers next year? Just any way to think about just given the cash and the burn and just trying to think about what the revenue opportunity could look like as you launch commercially and how investors get comfortable with that burn? Obviously if the revenue start to accelerate, it gives people some confidence. Just kind of any anything you can help with a funnel or how to think about the early traction that you might be able to achieve over the first couple years with your first targeted assays.

Yes. I think the way to think about that, I wouldn't necessarily kind of answer a question of how many customers or so forth. What I will say is if you go back through the remarks that Parag made in terms of the rollout of these different assays and as well for you and for investors, when we update our investor presentation and our SEC filings by end of day today after market close, you'll also find a visual of our timeline. What you'll see is where we are with our tau assay, which is -- which we expect to have in general availability with the instrument launch, AKT1 as well. You'll see oncology proteoforms 2 and 3, which are slated for the middle of the year lined up with platform launch and then slightly after for general availability for the third. We've previously said that the ones we're working on today in development are AKT1, p53, and EGFR, so those are likely to be the 3 in oncology. From that point, you also see that as we move forward, that we continue to add proteoform assays, and on that chart you'll see us go through 5, 6, 7, 8, 9, 10 and so forth. So there's a lot of content there. And then as well on that slide, what you'll see is something Parag talked about in his opening remarks, which is that we have a set of enhancements to these assays, some enhancements that affect all the assays, some that are assay-specific, that enable us to introduce new sample types like cerebrospinal fluid for tau, that enable us to have lower sample inputs so we can support blood and oncology. And those types of advances are slated to be introduced on a steady schedule as well. When you take all of those together, we think that is a substantial commercial opportunity. And so for us, when you ask how many customers, I think that we're going to have plenty of customers on early access and I'm excited about that. I also think that we're going to have enough content to start to drive instrument demand. And with a roughly $1 million deal, that's the biggest lever on the top line in the near term. I'm not going to put a size and shape around that opportunity. But as we start to get into next year, I think we'll have more for you. But, in total, I think it's an exciting opportunity. It's just a little too early for us to put some numbers around it.

This is Thomas on for Subbu. Maybe just to pick up there on pre-orders, other peers have noted academic markets appear to be largely stabilizing. But just curious the latest you've seen in that end market and just the confidence you have in customers having the funds to commit to pre-orders for full price instrumentation towards the end of this year and into next?

Maybe I'll take that one, Thomas. So I think let's first kind of separate the customers in the U.S. and North America more broadly. In the biopharma space where we are less active today but expect that we will begin to grow our book of business, as we start to move these products through our roadmap. I think that what we've seen in conversations is that budgets are stable, that they're not affected by any external forces. And I think that some of the early results that we've seen out of the Dx and tools space and the larger caps have supported that. And that's what we're seeing as well. On the academic nonprofit research side where NIH funding and government funding is a significant factor, I think that what I've said before is probably what we're seeing now, which is that there's still some -- there's still a little bit of choppiness out there where, I was expecting this much, but I only got that much. And I think this is coming but it's a little delayed. But that choppiness is probably improving a little bit. And as well, as we think about the types of customers that we're going after on the academic side, there certainly is NIH dollars. There are NIH dollars that are going into funding those projects for our customers. And we're continuing to see that they're getting funded, that they're having dollars available. And so I think that I'd say that, that market -- that funding climate is improving a little bit, and we'll see how it is as we start to head into next year.

Great. And then maybe just to follow up on the revenue this year. Just curious what the split is for the second half in terms of grant revenue from Michael J. Fox and then just what you can expect from the services side as well?

Sure, Thomas, I can speak to that. As you heard us say, we reported our first revenue with Michael J. Fox this quarter. That was the primary driver of revenue. And now that we're -- that work is underway. I would anticipate that we would see fairly steady revenue coming from that -- those efforts through 2026 and into 2027, although the amounts might vary a little bit depending on the type of work that's being done in any particular quarter. We are -- we do have a sales team now and they're engaging with customers every day. The -- in that case, I would expect some additional early access customers, although I don't anticipate that to be a major driver of revenue this year.

Thomas, one of the things I do want to add to that, just to point out so that you think about it from a modeling perspective and we think about our top line. Today, our sales team is doing early activities -- early market activities around oncology, but largely they're out selling the tau assay. Our tau assay today only supports brain tissue as a sample type. And brain tissue is a fairly rare sample in neurodegeneration research. And so roughly 9 out of 10 of those conversations is holy mackerel. This is amazing technology. Do you support CSF or blood? And the answer is it's coming soon. So that's 9 out of 10 of our sales cycles. With oncology, the prevalence of tissue samples is much more normal, much more common and the market size is larger. So we think that in the near term, that puts oncology at 5 to 10 times the size of serviceable opportunity relative to neurodegeneration, not because of raw market size but because of sample types that we support. And we expect that enabling biofluids in oncology will be a little bit easier than neurodegeneration, which is what Parag said that CSF support for neurodegeneration for tau specifically is something we expect in '28, and for oncology we expect to be able to reach there earlier. And you'll see all of that on our roadmap, which will be in our filings at the end of the day today. With that, I would think about it as AKT1 being a significant unlock of serviceable opportunity for us. And so if that early access comes here, this year, as we start to enter the beginning of next year, I think that you'll start seeing the oncology business ramping significantly faster than neurodegeneration just because of the way that the various sample types supported rollout on our roadmap.

[Operator Instructions] And I'm not showing any further questions at this time. And as such, this does conclude today's presentation. We thank you for your participation. You may now disconnect and have a wonderful day.